Alnylam Licenses IP Covering RNAi Applications in Vaccines
June 17, 2010
Alnylam Licenses IP Covering RNAi Applications in Vaccines
The deals are with the Mount Sinai School of Medicine and the University of Queensland in Australia, which have been collaborating with the company on developing vaccines for flu and cancer.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Sylentis Picks up Option to Alnylam RNAi IP
November 17, 2011 / Gene Silencing News - Despite Recent Changes in Plans, Big Pharma Maintains RNAi Partnerships
December 9, 2010 / Gene Silencing News - Alnylam, Medtronic to Get Funding for Huntington's Disease Program
November 4, 2010 / Gene Silencing News - Novartis Says 'No' on Alnylam IP Option as Alternate RNAi Approaches Gain Traction
September 30, 2010 / Gene Silencing News - Snapshot: Partnership Goals, Track Records in the RNAi/miRNA Space
July 22, 2010 / Gene Silencing News